Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs Green Cap Health

Gala Health
Graded #17

Higher grade

vs+19.700000000000003
Green Cap Health
Graded #258

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 63.2/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +10
84
74
Dose & formulationGala Health +19
83
64
Clinical oversightGala Health +17
85
68
Labs & monitoringGala Health +31
83
52
FulfillmentGala Health +32
88
56
Contract termsGala Health +19
66
47
Gala Health · left barGreen Cap Health · right bar

The numbers

MetricGala HealthGreen Cap Health
WeighScore82.9/10063.2/100
GradeB−C
Scorecard rank#17#258
SemaglutideNot disclosed$129/mo (6-month plan, compounded)
Tirzepatide$179/mo (yearly subscription)$199/mo (6-month plan, compounded)
CoverageAll 50 states1 state
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Green Cap Health

Graded #258 · C

Strengths

  • Vertically integrated: the prescribing practice and the compounding pharmacy are the same company, so the supply chain is short and named
  • Same-day provider review and 1-3 day discreet shipping
  • The full commitment ladder is published, so the month-to-month rate and the six-month rate can be compared directly

Where it loses points

  • The advertised $2.63-a-day and $79 first-month figures do not correspond to any purchasable plan; the cheapest real rates are $129/mo semaglutide and $199/mo tirzepatide, both on six-month commitments, and month-to-month is $179 and $279
  • The terms disclose a separate Weight Management Program Membership Fee, charged periodically on top of the plan and revealed only during checkout — it appears on no product page
  • The terms also state recurring fees are charged in advance without seeking any additional authorisation
  • Service is Texas-only, so nothing here is available to a reader outside that state
  • The site's terms link out to lifemd.com's terms — the legal text is another company's

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard